Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Immutep Limited

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2024 Diversified Communications. All rights reserved.